The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Open accessAbstract
Direct-acting cannabinoid receptor agonists are well known to reduce hyperalgesic responses and allodynia after nerve injury, although their psychoactive side effects have damped enthusiasm for their therapeutic development. Alternatively, inhibiting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the principal enzymes responsible for the degradation of the respective endogenous cannabinoids, anandamide (AEA) and 2-arachydonylglycerol (2-AG), reduce nociception in a variety of nociceptive assays, with no or minimal behavioral effects. In the present study we tested whether inhibition of these enzymes attenuates mechanical allodynia, and acetone-induced cold allodynia in mice subjected to chronic constriction injury of the sciatic nerve. Acute administration of the irreversible FAAH inhibitor, cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597), or the reversible FAAH inhibitor, 1-oxo-1-[5-(2-pyridyl)-2-yl]-7-phenylheptane (OL-135), decreased allodynia in both tests. This attenuation was completely blocked by pretreatment with either CB(1) or CB(2) receptor antagonists, but not by the TRPV1 receptor antagonist, capsazepine, or the opioid receptor antagonist, naltrexone. The novel MAGL inhibitor, 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) also attenuated mechanical and cold allodynia via a CB(1), but not a CB(2), receptor mechanism of action. Whereas URB597 did not elicit antiallodynic effects in FAAH(-/-) mice, the effects of JZL184 were FAAH-independent. Finally, URB597 increased brain and spinal cord AEA levels, whereas JZL184 increased 2-AG levels in these tissues, but no differences in either endo-cannabinoid were found between nerve-injured and control mice. These data indicate that inhibition of FAAH and MAGL reduces neuropathic pain through distinct receptor mechanisms of action and present viable targets for the development of analgesic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, other studies using knockout mice or selective inhibitors of CB 1 or CB 2 receptors show no alterations of nociceptive behavior in neuropathic pain models (Kinsey et al, 2009(Kinsey et al, , 2010) ) though ceiling effects and other methodological differences between studies may have precluded the detection of enhanced nociceptive behavior.”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Kinsey et al, 2009
In the citing paper
“though ceiling effects and other methodological differences between studies may have precluded the detection of enhanced nociceptive behavior.”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Kinsey et al, 2009
In the citing paper
“Additionally both OL135 and URB597 are antinociceptive in FAAH+/+ mice, but fail to produce an effect in FAAH-/- mice.59”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [59]
In the citing paper
“OL135 and URB597 attenuate cold and mechanical allodynia in a manner that is dependent upon activation of both CB1 and CB2 receptors.59”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [59]
In the citing paper
“The novel MGL inhibitor, JZL184, attenuates CCI-induced mechanical and cold allodynia through indirect activation of the CB1 receptor; JZL184 was efficacious in attenuating neuropathic nociception in both FAAH+/+ and FAAH-/- mice.59”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,740
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Spared nerve injury: an animal model of persistent peripheral neuropathic pain
Décosterd, I., & Woolf, C. J. (2000) · Pain · doi:10.1016/s0304-3959(00)00276-1 · Cited by 2,317
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Self-citationGaliègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D. J., Fur, G. L., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,776
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S. E., Allchorne, A. J., Poole, S., Bonventre, J. V., & Woolf, C. J. (2001) · Nature · doi:10.1038/35068566 · Cited by 1,282
Cited by
Sorted by citations
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2616 · Cited by 641
Self-citationLipolysis – A highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores
Lass, A., Zimmermann, R., Oberer, M., & Zechner, R. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.10.004 · Cited by 677
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 434
Self-citationLong, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., Burston, J. J., Sim‐Selley, L. J., Lichtman, A. H., Wiley, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909411106 · Cited by 405
Self-citationHuggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
Neuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 389
Chemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
Self-citationThe pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 317
Self-citationCannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Self-citationSavinainen, J. R., Saario, S. M., & Laitinen, J. T. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02280.x · Cited by 297
Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 285
Nomura, D. K., Lombardi, D. P., Chang, J. W., Niessen, S., Ward, A. M., Long, J. Z., Hoover, H. H., & Cravatt, B. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.05.009 · Cited by 275
Self-citationFiskerstrand, T., Hmida, D., Johansson, S., Abderrahim, M., Haukanes, B. I., Drouot, N., Zimmermann, J., Cole, A. J., Vedeler, C. A., Bredrup, C., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.08.002 · Cited by 238
Ahn, K., Smith, S. E., Liimatta, M. B., Beidler, D. R., Sadagopan, N., Dudley, D. T., Young, T., Wren, P. B., Zhang, Y., Swaney, S. M., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180257 · Cited by 232
Self-citationChanda, P. K., Gao, Y., Mark, L., Btesh, J., Strassle, B. W., Lu, P., Piesla, M. J., Zhang, M.-Y., Bingham, B., Uveges, A. J., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068304 · Cited by 236
2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain
Baggelaar, M. P., Maccarrone, M., & van der Stelt, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.05.002 · Cited by 224
The Role of the Endocannabinoid System in Pain
Woodhams, S. G., Sagar, D. R., Burston, J. J., & Chapman, V. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46450-2_7 · Cited by 216
Therapeutic potential of monoacylglycerol lipase inhibitors
Mulvihill, M. M., & Nomura, D. K. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.10.025 · Cited by 205
Animal models of chronic pain: Advances and challenges for clinical translation
Burma, N. E., Leduc‐Pessah, H., Fan, C. Y., & Trang, T. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23768 · Cited by 198
Chang, J. W., Niphakis, M. J., Lum, K. M., Cognetta, A. B., Wang, C., Matthews, M. L., Niessen, S., Buczynski, M. W., Parsons, L. H., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.03.009 · Cited by 196
Self-citationInhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain
Roques, B. P., Fournié‐Zaluski, M., & Wurm, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3673 · Cited by 198
Cannabinoids and Pain: Sites and Mechanisms of Action
Starowicz, K., & Finn, D. P. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.05.003 · Cited by 203
Pain hypersensitivity mechanisms at a glance
Gangadharan, V., & Kuner, R. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.011502 · Cited by 187
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 188
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
Ignatowska-Jankowska, B. M., Baillie, G. L., Kinsey, S. G., Crowe, M. S., Ghosh, S., Owens, R. A., Damaj, M. I., Poklis, J. L., Wiley, J. L., Zanda, M., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.148 · Cited by 178
Self-citationKinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
Self-citationKinsey, S. G., Wise, L. E., Ramesh, D., Abdullah, R., Selley, D. E., Cravatt, B. F., & Lichtman, A. H. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201426 · Cited by 169
Self-citationGuindon, J., Lai, Y., Takacs, S. M., Bradshaw, H. B., & Hohmann, A. G. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.013 · Cited by 160
Evaluation of NHS Carbamates as a Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors
Niphakis, M. J., Cognetta, A. B., Chang, J. W., Buczynski, M. W., Parsons, L. H., Byrne, F., Burston, J. J., Chapman, V., & Cravatt, B. F. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400116z · Cited by 157
Self-citationAlhouayek, M., Masquelier, J., Cani, P. D., Lambert, D. M., & Muccioli, G. G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314017110 · Cited by 152
Grabner, G. F., Zimmermann, R., Schicho, R., & Taschler, U. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.033 · Cited by 153
Monoacylglycerol lipase (MAGL) as a promising therapeutic target
Gil-Ordóñez, A., Martín‐Fontecha, M., Ortega‐Gutiérrez, S., & López-Rodríguez, M. L. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.036 · Cited by 146
Lomazzo, E., Bîndilă, L., Remmers, F., Lerner, R., Schwitter, C., Hoheisel, U., & Lutz, B. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.198 · Cited by 143
Snider, N. T., Walker, V. J., & Hollenberg, P. F. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.001081 · Cited by 136
The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH)
Otrubova, K., Ezzili, C., & Boger, D. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.096 · Cited by 134
Self-citationCannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy
Khasabova, I. A., Khasabov, S., Paz, J., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0403-12.2012 · Cited by 129
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
van Egmond, N., Straub, V. M., & van der Stelt, M. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-112741 · Cited by 137
Ignatowska‐Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., Tao, Q., O' Neal, S. T., Walentiny, D. M., Wiley, J. L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12298 · Cited by 128
Self-citationGhosh, S., Wise, L. E., Chen, Y., Gujjar, R., Mahadevan, A., Cravatt, B. F., & Lichtman, A. H. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.06.020 · Cited by 127
Self-citationLuchicchi, A., & Pistis, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8299-0 · Cited by 130
Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Guindon, J., Guijarro, A. I., Piomelli, D., & Hohmann, A. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01192.x · Cited by 120
Kinsey, S. G., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.04.001 · Cited by 118
Self-citationLötsch, J., Weyer-Menkhoff, I., & Tegeder, I. (2017) · European Journal of Pain · doi:10.1002/ejp.1148 · Cited by 123
Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long, J. Z., Ezzili, C., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01445.x · Cited by 116
Self-citationGriebel, G., Pichat, P., Beeské, S., Leroy, T., Redon, N., Jacquet, A., Françon, D., Bert, L., Even, L., Lopez‐Grancha, M., et al. (2015) · Scientific Reports · doi:10.1038/srep07642 · Cited by 113
The discovery and development of analgesics: new mechanisms, new modalities
Burgess, G. M., & Williams, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43195 · Cited by 109
The role of endocannabinoids in pain modulation
Zogopoulos, P., Vasileiou, I., Patsouris, E., & Theocharis, S. E. (2013) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12008 · Cited by 112
Enhanced endocannabinoid tone as a potential target of pharmacotherapy
Toczek, M., & Malinowska, B. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.04.054 · Cited by 108
Tchantchou, F., Tucker, L. B., Fu, A. H., Bluett, R. J., McCabe, J. T., Patel, S., & Zhang, Y. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.006 · Cited by 103
Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A., Kerwin, A. A., Armijo, L. M., Kuhn, M. N., Thakur, G. A., Makriyannis, A., & Milligan, E. D. (2012) · Pain · doi:10.1016/j.pain.2012.02.015 · Cited by 99
Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications
Pertwee, R. G. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003649 · Cited by 100
Hwang, J., Adamson, C. L., Butler, D., Janero, D. R., Makriyannis, A., & Bahr, B. A. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.06.003 · Cited by 100
Starowicz, K., Makuch, W., Korostyński, M., Małek, N., Ślęzak, M., Żychowska, M., Petrosino, S., PETROCELLIS, L. D., Cristino, L., Przewłocka, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060040 · Cited by 97
Dynamic Regulation of the Endocannabinoid System: Implications for Analgesia
Sagar, D. R., Gaw, A. G., Okine, B. N., Woodhams, S. G., Wong, A., Kendall, D. A., & Chapman, V. (2009) · Molecular Pain · doi:10.1186/1744-8069-5-59 · Cited by 99
Kinsey, S. G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P. S., Razdan, R. K., Selley, D. E., Damaj, M. I., & Lichtman, A. H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.09.004 · Cited by 94
Self-citationKinsey, S. G., Nomura, D. K., O’Neal, S. T., Long, J. Z., Mahadevan, A., Cravatt, B. F., Grider, J. R., & Lichtman, A. H. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175778 · Cited by 93
Self-citationEndocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase
Long, J. Z., LaCava, M. E. F., Jin, X., & Cravatt, B. F. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m012153 · Cited by 95
Self-citationSelective Monoacylglycerol Lipase Inhibitors: Antinociceptive versus Cannabimimetic Effects in Mice
Ignatowska-Jankowska, B. M., Wilkerson, J. L., Mustafa, M. A., Abdullah, R. A., Niphakis, M. J., Wiley, J. L., Cravatt, B. F., & Lichtman, A. H. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222315 · Cited by 92
Self-citationKinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.022 · Cited by 87
Self-citationKohnz, R. A., & Nomura, D. K. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00047a · Cited by 86
The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry–Biology Interface
Boger, D. L. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b02088 · Cited by 80
Self-citationComparative biology of pain: What invertebrates can tell us about how nociception works
Burrell, B. D. (2017) · Journal of Neurophysiology · doi:10.1152/jn.00600.2016 · Cited by 81
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands
Davis, M. P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918603 · Cited by 81
Wilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
Self-citationEndocannabinoid-Based Therapies
Piomelli, D., & Tagne, A. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-021800 · Cited by 82
Kerr, D., Harhen, B., Okine, B. N., Egan, L. J., Finn, D. P., & Roche, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02237.x · Cited by 77
Nadal, X., La Porta, C., Andreea Bura, S., & Maldonado, R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.077 · Cited by 76
Dynamic changes to the endocannabinoid system in models of chronic pain
Sagar, D. R., Burston, J. J., Woodhams, S. G., & Chapman, V. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0390 · Cited by 77
Khasabova, I. A., Chandiramani, A., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.03.007 · Cited by 75
Starowicz, K., Makuch, W., Osikowicz, M., Piscitelli, F., Petrosino, S., Marzo, V. D., & Przewłocka, B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.021 · Cited by 78
Alkaitis, M. S., Solórzano, C., Landry, R. P., Piomelli, D., DeLeo, J. A., & Romero-Sandoval, E. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010891 · Cited by 72
Endocannabinoid System and Migraine Pain: An Update
Greco, R., Demartini, C., Zanaboni, A. M., Piomelli, D., & Tassorelli, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00172 · Cited by 71
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model
Barnes, N. S. A., Mitchell, V. A., Kazantzis, N. P., & Vaughan, C. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13337 · Cited by 72
Ramesh, D., Gamage, T. F., Vanuytsel, T., Owens, R. A., Abdullah, R. A., Niphakis, M. J., Shea‐Donohue, T., Cravatt, B. F., & Lichtman, A. H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.269 · Cited by 73
Self-citationRea, K., Olango, W. M., Okine, B. N., Madasu, M. K., McGuire, I. C., Coyle, K., Harhen, B., Roche, M., & Finn, D. P. (2013) · Pain · doi:10.1016/j.pain.2013.09.012 · Cited by 69
Caprioli, A., Coccurello, R., Rapino, C., Serio, S. D., Tommaso, M. D., Vertechy, M., Vacca, V., Battista, N., Pavone, F., Maccarrone, M., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191403 · Cited by 68
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease
Nascimento, G. C., Ferrari, D. P., Guimarães, F. S., Bel, E. A. D., Bortolanza, M., & Ferreira‐Junior, N. C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107808 · Cited by 69
Wilkerson, J. L., Niphakis, M. J., Grim, T. W., Mustafa, M. A., Abdullah, R. A., Poklis, J. L., Dewey, W. L., Akbarali, H. I., Banks, M. L., Wise, L. E., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229971 · Cited by 68
Self-citationLatest advances in the discovery of fatty acid amide hydrolase inhibitors
Bisogno, T., & Maccarrone, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.780021 · Cited by 65
Rahn, E. J., Deng, L., Thakur, G. A., Vemuri, K. V., Zvonok, A. M., Lai, Y. Y., Makriyannis, A., & Hohmann, A. G. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-27 · Cited by 65
Douglass, J. D., Zhou, Y. X., Wu, A., Zadrogra, J. A., Gajda, A. M., Lackey, A. I., Lang, W., Chevalier, K. M., Sutton, S. W., Zhang, S., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m058586 · Cited by 71
Sensory neuron–associated macrophages as novel modulators of neuropathic pain
Silva, C. E. A., Guimarães, R. M., & Cunha, T. M. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000873 · Cited by 67
A Binding Site for Nonsteroidal Anti-inflammatory Drugs in Fatty Acid Amide Hydrolase
Bertolacci, L., Romeo, E., Veronesi, M., Magotti, P., Albani, C., Dionisi, M., Lambruschini, C., Scarpelli, R., Cavalli, A., Vivo, M. D., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja308733u · Cited by 64
Wise, L. E., Long, K. A., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200130s · Cited by 66
Self-citationMalek, N., Mrugala, M., Makuch, W., Kolosowska, N., Przewlocka, B., Binkowski, M., Czaja, M., Morera, E., Di Marzo, V., & Starowicz, K. (2015) · Pain · doi:10.1097/j.pain.0000000000000132 · Cited by 63
Long, J. Z., Jin, X., Adibekian, A., Li, W., & Cravatt, B. F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016976 · Cited by 62
Self-citationShen, J., Fox, L. E., & Cheng, J. (2013) · Pain Medicine · doi:10.1111/pme.12057 · Cited by 61
Deng, L., Cornett, B., Mackie, K., & Hohmann, A. G. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098483 · Cited by 60
Tabrizi, M. A., Baraldi, P. G., Baraldi, S., Ruggiero, E., Stefano, L. D., Rizzolio, F., Mannelli, L. D. C., Ghelardini, C., Chicca, A., Lapillo, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01845 · Cited by 62
Jiang, M., Huizenga, M. C. W., Wirt, J. L., Pálóczi, J., Amedi, A., van den Berg, R. J. B. H. N., Benz, J., Collin, L., Deng, H., Di, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43606-3 · Cited by 63
Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system
Starowicz, K., & Przewłocka, B. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0392 · Cited by 60
Targeting the cannabinoid system for pain relief?
Chiou, L., Hu, S. S., & Ho, Y. (2013) · Acta anaesthesiologica Taiwanica · doi:10.1016/j.aat.2013.10.004 · Cited by 59
Okine, B. N., Norris, L. M., Woodhams, S. G., Burston, J. J., Patel, A., Alexander, S. P. H., Barrett, D. A., Kendall, D. A., Bennett, A. J., & Chapman, V. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02028.x · Cited by 56
Metadata
- Authors
- Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H.
- Affiliations
- Virginia Commonwealth University (US)
- Scripps Research Institute (US)
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 330
- Issue
- 3
- Pages
- 902-910
- ISSN
- 0022-3565 (ISSN-L)
- PMC
- PMC2729802
- OpenAlex
- W2132380973
- Cited by
- 330
- References
- 43
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 15 · 2020: 9 · 2019: 14 · 2018: 21 · 2017: 24 · 2016: 16 · 2015: 21 · 2014: 35 · 2013: 29 · 2012: 33
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institute of International Education
- National Institute on Drug Abuse (DA015197, P01DA009789, DA-017259, R01DA015197, DA009789-11, DA007027-32, P01DA017259, DA 009789, DA015648, T32DA007027, DA007027)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- neuropathic pain, endocannabinoid system, fatty acid amide hydrolase, monoacylglycerol lipase, anandamide, 2-arachidonoylglycerol, CB1 receptor, CB2 receptor, URB597, JZL184, chronic constriction injury, mechanical allodynia, cold allodynia, analgesic drug development
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Arachidonic Acids, Benzamides, Carbamates, Cold Temperature, Enzyme Inhibitors, Glycerides, Hyperalgesia, Male, Mice, Inbred C57BL, Monoacylglycerol Lipases, Narcotic Antagonists, Pain, Pain Measurement, Peripheral Nervous System Diseases, Piperidines, Pyridines, Analgesics, Non-Narcotic, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, TRPV Cation Channels, Mice, Benzodioxoles, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review